Identification of coinfections by viral and bacterial pathogens in covid-19 hospitalized patients in peru: Molecular diagnosis and clinical characteristics

The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 in...

Descripción completa

Detalles Bibliográficos
Autores: Pérez Lazo, Giancarlo, Silva Caso, Wilmer, Valle Mendoza, Juana del, Morales Moreno, Adriana, Ballena López, José, Soto Febres, Fernando, Martins Luna, Johanna Elizabeth, Carrillo Ng, Hugo, Valle Mendoza, Luis Javier del|||0000-0001-9916-1741, Kym, Sungmin, Aguilar Luis, Miguel Angel, Peña Tuesta, Isaac, Tinco Valdez, Carmen, Illescas, Luis Ricardo
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Politècnica de Catalunya (UPC)
Repositorio:UPCommons. Portal del coneixement obert de la UPC
Idioma:inglés
OAI Identifier:oai:upcommons.upc.edu:2117/365450
Acceso en línea:https://hdl.handle.net/2117/365450
https://dx.doi.org/10.3390/antibiotics10111358
Access Level:acceso abierto
Palabra clave:COVID-19 (Disease)
Antibiotics
Virology
Coinfections
COVID-19
antibiotics
COVID-19 (Malaltia)
Antibiòtics
Virologia
Àrees temàtiques de la UPC::Ciències de la salut::Medicina
Descripción
Sumario:The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae. View Full-Text

Similares en LA Referencia